Derek Norris

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Neil P. Shah, Chris Tran, Francis Y. Lee et al. · Science · 2004 · 1.8K citations

Imatinib Resistance, Imatinib-resistant Bcr-abl Mutants, Chronic Myeloid Leukemia +14

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text

Drug Target, Preclinical Assays, Pharmacotherapy +19

2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of <i>N</i> -(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent <i>pan</i> -Src Kinase Inhibitor

Jagabandhu Das, Ping Chen, Derek Norris et al. · Journal of Medicinal Chemistry · 2006 · 393 citations · Full text

Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors

Ashvinikumar V. Gavai, Claude Quesnelle, Derek Norris et al. · ACS Medicinal Chemistry Letters · 2015 · 88 citations · Full text

Solid Tumors, Pharmacotherapy, Tumor Biology +18

Rational Design and Synthesis of an Orally Active Indolopyridone as a Novel Conformationally Constrained Cannabinoid Ligand Possessing Antiinflammatory Properties

Stephen T. Wrobleski, Ping Chen, John Hynes et al. · Journal of Medicinal Chemistry · 2003 · 57 citations · Full text

Combinatorial Chemistry, Orally Active Indolopyridone, Pharmacotherapy +17